Anika reports Q4 2021 revenue $35.8M (+10% YoY); full year $147.8M (+13%); guides FY2022 low-to-mid single digit growth

Anika Therapeutics, Inc.

Q4 2021 revenue $35.8M (+10% YoY); net loss $5.8M ($0.40 diluted) vs $15.7M loss prior year.
Full-year 2021 revenue $147.8M (+13% YoY); net income $4.1M ($0.28 diluted) vs $24.0M loss in 2020.
Adjusted net loss Q4 $3.2M ($0.23 diluted) vs adjusted net income $1.7M prior year; adjusted EBITDA loss $0.2M vs $4.0M.
FY2022 guidance: revenue growth low-to-mid single digit; Joint Preservation mid-single to low-double digit, OA Pain low-single digit.
Cash balance $94.4M; operating cash flow $9.0M for full year; completed enrollment of Cingal pilot trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.